You are here:

The Epilepsy Society launches 'Safe Mum, Safe Baby' campaign

Published on


The Epilepsy Society launches 'Safe Mum, Safe Baby' campaign

The Epilepsy Society is launching a new campaign - ‘Safe Mum, Safe Baby’ - calling for safer epilepsy medications in pregnancy. We need to hear from women about the challenges they face when planning a family and ensuring they have good seizure control and that their baby will not be harmed. Find out how you can lend your voice to our campaign.

Six pregnant women looking into the camera

We are calling on the government to fund research into epilepsy medication so that babies will not be born with preventable disabilities caused by their mothers’ life saving drugs. 

A new review has shown that some of the most commonly prescribed epilepsy medications can pose an increased risk for babies during pregnancy.

While lamotrigine and levetiracetam have been shown to be the safest medications during pregnancy, data has highlighted an increased risk with many other medications.

It is well known that valproate carries a high risk of harm to any baby exposed to it during pregnancy, but a report from the Commission on Human Medicines has also shown that there are risks linked to other drugs including carbamazepine, topiramate, phenytoin and phenobarbital.

You can read the full review here.

Please note, you should never stop taking your medication without consulting your doctor.

The Epilepsy Society is launching a new campaign – Safe Mum, Safe Baby - to ensure that all women and girls of childbearing age are aware of the risks and are called in for an annual review to discuss their treatment options with their neurologist or GP.

We are also calling on the Government to increase funding into research around why some epilepsy medications can cause physical and neurodevelopmental disabilities in babies exposed to them during pregnancy.

The Medicines and Healthcare products Regulatory Agency (MHRA) has been working with NHS Digital to develop a registry to monitor both the use of valproate and any children exposed to the drug during pregnancy. We are asking the MHRA, as a matter of urgency, to extend the registry to include individual data relating to all anti-epileptic drugs, so that researchers can begin to understand why some pregnancies are more vulnerable than others.

But we also need your help.

If you would like to join us in our Safe Mum, Safe Baby campaign by talking about your own experience and the challenges faced by women in ensuring that their seizures are controlled during pregnancy and their baby is safe, we would love to hear from you. Please email us at and tells a little about your epilepsy, the concerns you may have around your medication and planning a family and why you are supporting our campaign.

We would also like to hear from anyone who feels their family has been affected by epilepsy medication during pregnancy.

Nicola Swanborough, Head of External Affairs said: “Our goal is to ensure that in the future no woman should have to worry that the medication she must take to control her seizures might affect the health and development of her baby.

“Research is key to understanding why these medications increase the risk of harm during pregnancy. The only thing that stands between research and knowledge is funding. We hope that the Government will respond to our campaign and help to ensure the health and happiness of future generations of children and their families.”


We send monthly e-newsletters to keep you informed with tips for managing epilepsy, the latest news, inspirational stories, fundraising opportunities and further information from Epilepsy Society.

Read our privacy policy

It is always your choice as to whether you want to receive information from us. You may opt-out of our marketing communications by clicking the ‘unsubscribe’ link at the end of our marketing emails or through our unsubscribe number 01494 601 300.